Beijing, China, January 13, 2026—Gan & Lee Pharmaceuticals. (hereinafter referred to as "Gan & Lee" stock code: 603087.SH) is pleased to announce the appointment of Dr. John Wang as Senior Vice President and Chief Strategy Officer (SVP & CSO), effective January 12, Eastern Time. Dr.Wang will oversee the company's business development and strategic collaborations, spearheading Gan & Lee's global expansion and portfolio diversification across multiple therapeutic areas.

Dr. Wang brings over 30 years of distinguished experience in the pharmaceutical industry, spanning R&D, corporate strategy, and commercialization. He possesses a proven track record in business development, including in-licensing, out-licensing, and alliance management. His expertise covers the entire lifecycle of strategic growth—from early-stage project evaluation and due diligence to cross-functional execution and global implementation.

Dr. Wang holds a Ph.D. in Pharmacology from the University of London and conducted postdoctoral research at Harvard University and Boston University School of Medicine. This robust scientific foundation is paired with a visionary approach to industry trends. His career began at Wyeth Pharmaceuticals, initially focusing on R&D in neuroscience and CVMD fields. He subsequently transitioned to business development and strategic partnerships, holding leadership roles at global pharmaceutical leaders including Sanofi, Merck, Eli Lilly, and Simcere Pharmaceutical Group. Over the course of his career, Dr.Wang has led or facilitated strategic collaborations and investments with a cumulative value exceeding USD 10 billion, demonstrating exceptional capabilities in resource integration and strategic execution.

Dr. Wei Chen, Chairman and CEO of Gan & Lee, stated, "Gan & Lee is at a critical stage of business transformation and global development. The addition of Dr. John Wang will further expand the company's in-depth collaborations with top-tier international pharmaceutical companies, biotech firms, and R&D institutions. This will accelerate the global clinical development and commercialization of our innovative pipeline, help us build a future-oriented global innovation system, enhance our international competitiveness, and inject strong momentum into the company's long-term sustainable development."

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.